BEI
NTLA icon

Benjamin Edwards Inc’s Intellia Therapeutics NTLA Stock Holding History

Benjamin Edwards Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
80,881
-1,682
-2% -$23.5K 0.01% 698
2026
Q1 		$1.06M Buy
82,563
+3,363
+4% +$42.8K 0.01% 741
2025
Q4 		$712K Buy
79,200
+14,350
+22% +$198K 0.01% 828
2025
Q3 		$1.12M Buy
64,850
+1,816
+3% +$22.4K 0.01% 648
2025
Q2 		$591K Buy
63,034
+1,126
+2% +$9.25K 0.01% 799
2025
Q1 		$440K Sell
61,908
-2,157
-3% -$21.8K 0.01% 826
2024
Q4 		$747K Buy
64,065
+6,396
+11% +$99.8K 0.01% 706
2024
Q3 		$1.18M Buy
57,669
+57,253
+13,763% +$1.32M 0.02% 551
2024
Q2 		$9K Sell
416
-146
-26% -$3.48K ﹤0.01% 624
2024
Q1 		$15K Buy
562
+35
+7% +$972 ﹤0.01% 605
2023
Q4 		$16K Sell
527
-317
-38% -$9.11K ﹤0.01% 555
2023
Q3 		$27K Buy
844
+78
+10% +$3.03K 0.01% 517
2023
Q2 		$31K Buy
766
+18
+2% +$730 0.01% 507
2023
Q1 		$28K Buy
748
+38
+5% +$1.49K 0.01% 512
2022
Q4 		$25K Buy
710
+141
+25% +$6.7K 0.01% 482
2022
Q3 		$32K Sell
569
-44
-7% -$2.73K 0.01% 454
2022
Q2 		$32K Buy
613
+6
+1% +$305 0.01% 471
2022
Q1 		$44K Sell
607
-81
-12% -$6.86K 0.01% 467
2021
Q4 		$81K Buy
688
+36
+6% +$4.51K 0.03% 372
2021
Q3 		$87K Sell
652
-198
-23% -$30K 0.05% 246
2021
Q2 		$138K Sell
850
-443
-34% -$34.5K 0.09% 188
2021
Q1 		$104K Sell
1,293
-8
-0.6% -$537 0.08% 198
2020
Q4 		$71K Sell
1,301
-593
-31% -$21.5K 0.06% 216
2020
Q3 		$38K Buy
1,894
+77
+4% +$1.61K 0.03% 242
2020
Q2 		$38K Hold
1,817
– – 0.03% 223
2020
Q1 		$22K Sell
1,817
-61
-3% -$822 0.02% 234
2019
Q4 		$28K Buy
1,878
+223
+13% +$3.1K 0.06% 150
2019
Q3 		$22K Sell
1,655
-36
-2% -$574 0.05% 162
2019
Q2 		$28K Buy
1,691
+640
+61% +$10.1K 0.07% 145
2019
Q1 		$18K Buy
+1,051
New +$15.7K 0.09% 169

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Benjamin Edwards Inc's NTLA Position: Q2 2026 in Review

Benjamin Edwards Inc reduced its Intellia Therapeutics (NTLA) stake by 2% in Q2 2026, selling an estimated $23.5K and leaving 80,881 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #698.

Benjamin Edwards Inc first reported a position in NTLA in Q1 2019 and has held it in 30 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Benjamin Edwards Inc held 80,881 shares of Intellia Therapeutics worth $1.37M as of Q2 2026.
  • Benjamin Edwards Inc sold 1,682 Intellia Therapeutics shares in Q2 2026, an estimated $23.5K.
  • Intellia Therapeutics made up 0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #698 holding.
  • Benjamin Edwards Inc first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.